Breaking News
February 22, 2019 - Growing number of cancer survivors, fewer providers point to challenge in meeting care needs
February 22, 2019 - Innovative compound offers a new therapeutic approach to treat multiple sclerosis
February 22, 2019 - $1.5 million grant to develop opioid treatment program for jail detainees
February 22, 2019 - FDA’s new proposed rule would update regulatory requirements for sunscreen products in the U.S
February 22, 2019 - Most Hip, Knee Replacements Last Decades, Study Finds
February 22, 2019 - Wellness problems prevalent among ob-gyn residents
February 22, 2019 - In the Spotlight: “The world is your oyster in geriatrics”
February 22, 2019 - Successful testing of multi-organ “human-on-a-chip” could replace animals as test subjects
February 22, 2019 - Analysis of cervical precancer shows decline in two strains of HPV
February 22, 2019 - Sugary stent eases suturing of blood vessels
February 22, 2019 - From surgery to psychiatry: A medical student reevaluates his motivations
February 22, 2019 - Is New App From Feds Your Answer To Navigating Medicare Coverage? Yes And No
February 22, 2019 - New pacemakers powered by heartbeats could reduce need for surgery
February 22, 2019 - The United States records highest drug overdose death rates
February 22, 2019 - Phase 1 data reinforce safety profile of new drug for treating Duchenne muscular dystrophy
February 22, 2019 - Vitamin D supplementation less effective in the presence of obesity, shows study
February 22, 2019 - Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
February 22, 2019 - An institutional effort to reduce the amount of opioids prescribed following lumbar surgery
February 22, 2019 - Failure to take statins leads to higher mortality rates | News Center
February 22, 2019 - New study explains why some patients report phantom sensations after limb amputation
February 22, 2019 - First motor-controlled heart valves implanted by Mainz University Medical Center
February 22, 2019 - Novel preclinical model mimics persistent interneuron loss seen in preterm infants
February 22, 2019 - Global health burden of glaucoma has increased, study reveals
February 22, 2019 - A holistic approach key to minimize treatment complexity in patients with interstitial lung disease
February 22, 2019 - 1 in 10 middle-aged Chinese adults are at high risk for heart disease, finds study
February 22, 2019 - More than half a million breast cancer patient’s lives saved by improvements in treatment
February 22, 2019 - Study finds no evidence that tougher policies prevent teenage cannabis use
February 22, 2019 - New blood test detects genetic disorders in fetuses
February 22, 2019 - Lower Self-Perception Observed in Children With Amblyopia
February 22, 2019 - Up to 15 percent of children have sleep apnea, yet 90 percent go undiagnosed
February 22, 2019 - Rare pulmonary defect prompts parents’ nationwide search for answers | News Center
February 22, 2019 - Lesbian and bisexual women at greater risk of being overweight, study finds
February 22, 2019 - UQ research may explain why vitamin D is essential for brain health
February 22, 2019 - Heart Attacks Rising Among Younger Women
February 22, 2019 - How your smartphone is affecting your relationship
February 22, 2019 - Orthopaedic surgeon receives prestigious award, $10 million grant | News Center
February 22, 2019 - New sepsis test could save thousands of lives
February 22, 2019 - Cervical cancer could be eradicated by 2100
February 21, 2019 - Sustained smoking cessation can lower risk of seropositive RA
February 21, 2019 - Thousands with chronic UTIs are not receiving the treatment they need
February 21, 2019 - Are teens getting high on social media? The surprising study seeking the pot-Instagram link
February 21, 2019 - Stanford expands biobank services | News Center
February 21, 2019 - Scientists identify link between drinking contexts and early onset intoxication among adolescents
February 21, 2019 - Strong social support may reduce cardiovascular disease risk in postmenopausal women
February 21, 2019 - Rapid expansion of interventions could prevent up to 13 million cases of cervical cancer within 50 years
February 21, 2019 - Motif Bio Receives Complete Response Letter From The FDA
February 21, 2019 - Researchers map previously unknown disease in children
February 21, 2019 - A skeptical look at popular diets: Going gluten-free
February 21, 2019 - Podcast: KHN’s ‘What The Health?’ How Safe Are Your Supplements?
February 21, 2019 - Factors associated with increased risk of developing surgical site infections
February 21, 2019 - Anticipatory signals in eye movements can help measure attentive capacity, learning with greater precision
February 21, 2019 - Study explores daily exposure to indoor air pollutants
February 21, 2019 - Evening exercise does not negatively affect sleep, may also reduce hunger
February 21, 2019 - Artificial intelligence technique can be used to identify alcohol misuse in trauma setting
February 21, 2019 - Overweight, obesity in adolescence associated with increased risk of renal cancer later in life
February 21, 2019 - BGU develops new AI platform for monitoring and predicting ALS progression
February 21, 2019 - Researchers discover a new promising target to improve HIV vaccines
February 21, 2019 - Brief Anesthesia in Infancy Does Not Mar Neurodevelopment
February 21, 2019 - Gaming system helps with autism diagnosis
February 21, 2019 - Heart Disease: Six Things Women Should Know
February 21, 2019 - More States Say Doctors Must Offer Overdose Reversal Drug Along With Opioids
February 21, 2019 - Researchers explore case studies focused on industries that kill more people than employed
February 21, 2019 - Only half of GP practice buildings are fit for purpose
February 21, 2019 - Intense exercise, fasting and hormones can enhance waste-protein removal, study shows
February 21, 2019 - Scientists can monitor brain activity to predict epileptic seizures few minutes in advance
February 21, 2019 - Study quantifies hepatic and intestinal mRNA expression of Ugt isoforms in rats
February 21, 2019 - ‘Apple-Shaped’ Body? ‘Pear-Shaped’? Your Genes May Tell
February 21, 2019 - Can we repair the brain? The promise of stem cell technologies for treating Parkinson’s disease
February 21, 2019 - Trump Plan To Beat HIV Hits Rough Road In Rural America
February 21, 2019 - PENTAX Medical introduces new electrosurgical and argon plasma coagulation platforms
February 21, 2019 - Trump plan to beat HIV hits rough road in rural America
February 21, 2019 - Eating blueberries every day could help decrease blood pressure
February 21, 2019 - ‘No Second Chances’ report calls for new measures to combat cardiovascular disease in Australia
February 21, 2019 - Mayo clinic researchers discuss local case studies of leprosy
February 21, 2019 - Scientists demonstrate key role of salt in allergic immune reactions
February 21, 2019 - Experts propose revising the criteria for diagnosis of Parkinson’s disease
February 21, 2019 - The med student and the machine
February 21, 2019 - Hey, Hey! Ho, Ho! Is Striking For School Nurses The Way To Go?
February 21, 2019 - Latest research encourages children to move out and learn through physical activity
February 21, 2019 - Proper oral hygiene and regular visits to dentist can promote heart health
FDA flags risks linked to improper use of ROM tests

FDA flags risks linked to improper use of ROM tests

image_pdfDownload PDFimage_print

The U.S. Food and Drug Administration today alerted women and their doctors about serious adverse events related to the improper use of tests intended as an aid in detecting if a pregnant woman’s water has broken (also known as a rupture of the membranes containing amniotic fluid). A rupture of the membranes (ROM) can pose immediate and severe risks to the patient and developing fetus without proper patient management and timely intervention.

As part of the agency’s commitment to transparency in notifying the public about potential public health concerns, the FDA issued a Letter to Health Care Providers to remind providers that the labeling for these tests specifies that they should not be used on their own to independently diagnose a ROM in pregnant women. These tests have only been cleared for marketing by the FDA to be used by healthcare providers in conjunction with other clinical assessments to make critical patient management decisions regarding whether a ROM has occurred.

“Our most fundamental obligation to the American public is providing patients with access to safe and effective medical products. Sometimes this includes alerting healthcare providers and the public regarding the potential safety issues that can arise when providers are not using devices as they are intended. This is especially pertinent in this case, where we are dealing with a potential risk to the safety and well-being of pregnant women and their fetuses,” said Courtney Lias, Ph.D., director, Division of Chemistry and Toxicology Devices in the FDA’s Center for Devices and Radiological Health. “Our review of the risks associated with improper use of these ROM tests is ongoing, but we want to be transparent with providers and patients about the information that we have indicating an issue, and provide recommendations to minimize the risks. This is another example of our recently released Medical Device Safety Action Plan in practice. We are committed to streamlining and modernizing how we implement postmarket actions to address device safety issues to better protect the Americans who rely on us. We will continue to monitor adverse events regarding these tests and will communicate further if there is additional information that will benefit women and their healthcare providers. We urge healthcare providers to carefully follow the labeled instructions for use on these tests.”

A ROM is when the amniotic membranes, in which the fetus develops, breaks. The ROM is a normal occurrence once a woman is in labor. However, if ROM occurs prior to the onset of labor, it can cause an increased risk of infection and injury to the fetus and the pregnant woman. Healthcare providers use ROM tests to aid in diagnosing ruptured membranes in pregnant women through analysis of vaginal secretions. ROM tests are point of care tests that provide on-site information to providers.

The FDA has received information that indicates healthcare providers may be relying solely on ROM test results when making critical patient management decisions, despite manufacturers’ labeling instructions that ROM tests should not be used on their own to independently assess whether a ROM has occurred. The FDA reviewed these devices through its premarket clearance pathway and concurred with the manufacturers’ labeling recommendations warning providers to not use these tests independently.

The FDA is concerned that misuse, relying solely on ROM tests without using other assessments (over reliance), and inaccurate interpretation of lab test results of ROM tests could result in an increased risk of fetal harm or death. In an ongoing assessment of medical device reports filed with the agency, the FDA has become aware of adverse events related to the use of ROM tests, including 15 fetal deaths and multiple reports of health complications in pregnant women. The test may provide a false negative result; without additional clinical assessment, providers may incorrectly assume ROM has not occurred. The agency is issuing communications today to share the most current information it has available.

The FDA is also urging pregnant women who may be concerned about amniotic membranes that may have ruptured too early, which can be characterized by either a rapid release of amniotic fluid or a small trickle, to contact their healthcare providers right away. Patients should speak with their healthcare providers about the signs and symptoms of ROM.

The FDA is also separately notifying the public of a voluntary recall for one brand of these products, the Amnisure ROM Test Strips, distributed between October 2017 and March 2018. Approximately 40,500 Amnisure tests have been recalled due to a device malfunction. These devices do not exhibit a control line, making it potentially difficult for healthcare providers to interpret the results of the test. At this time, the agency is not aware of adverse events related to the recalled products. The FDA will continue to communicate with the manufacturer regarding the recall of these products and will provide updated information if it becomes available. This recall is unrelated to the improper use of the tests and the FDA is not aware of device malfunctions associated with any other ROM tests made by other manufacturers.

The FDA will continue closely monitoring reports of adverse events associated with ROM tests. The agency will keep the public informed if significant new information becomes available. Patients, providers and healthcare facilities are encouraged to report adverse events to MedWatch, the FDA Safety Information and Adverse Event Reporting program.

Source:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616137.htm

Tagged with:

About author

Related Articles